ES2963727R1 - Nutraceutical or pharmaceutical composition for use in the treatment and/or prevention of conditions or pathologies characterized by magnesium deficiency - Google Patents
Nutraceutical or pharmaceutical composition for use in the treatment and/or prevention of conditions or pathologies characterized by magnesium deficiency Download PDFInfo
- Publication number
- ES2963727R1 ES2963727R1 ES202390217A ES202390217A ES2963727R1 ES 2963727 R1 ES2963727 R1 ES 2963727R1 ES 202390217 A ES202390217 A ES 202390217A ES 202390217 A ES202390217 A ES 202390217A ES 2963727 R1 ES2963727 R1 ES 2963727R1
- Authority
- ES
- Spain
- Prior art keywords
- nutraceutical
- prevention
- treatment
- conditions
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000008167 Magnesium Deficiency Diseases 0.000 title 1
- 235000004764 magnesium deficiency Nutrition 0.000 title 1
- 239000002417 nutraceutical Substances 0.000 title 1
- 235000021436 nutraceutical agent Nutrition 0.000 title 1
- 230000007170 pathology Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102021000014504A IT202100014504A1 (en) | 2021-06-04 | 2021-06-04 | “Nutraceutical or pharmaceutical composition for use in the treatment and/or prevention of conditions or pathologies characterized by magnesium deficiency” |
PCT/IB2022/055491 WO2022254414A2 (en) | 2021-06-04 | 2022-06-14 | Nutraceuticalor pharmaceutical composition for the use in the treatment and/or in the prevention of conditions or diseases characterized by magnesium deficiency |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2963727A2 ES2963727A2 (en) | 2024-04-01 |
ES2963727R1 true ES2963727R1 (en) | 2024-05-07 |
Family
ID=77801811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES202390217A Pending ES2963727R1 (en) | 2021-06-04 | 2022-06-14 | Nutraceutical or pharmaceutical composition for use in the treatment and/or prevention of conditions or pathologies characterized by magnesium deficiency |
Country Status (3)
Country | Link |
---|---|
ES (1) | ES2963727R1 (en) |
IT (1) | IT202100014504A1 (en) |
WO (1) | WO2022254414A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019239372A1 (en) * | 2018-06-13 | 2019-12-19 | Pharmanutra S.P.A. | Composition comprising sucrosomial minerals containing mineral salts for use in conditions of deficiency of such minerals |
WO2021099976A1 (en) * | 2019-11-19 | 2021-05-27 | Neilos S.r.l. | A nutraceutical or pharmaceutical composition comprising iron pyrophosphate for use in the treatment and/or prevention of conditions or diseases characterized by iron deficiency |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1318597B1 (en) * | 2000-06-23 | 2003-08-27 | A C R Applied Coating Res S A | USE OF A HIGH CONTENT OF EPREGELATINIZED ACETYLATED AMYLOSE. |
-
2021
- 2021-06-04 IT IT102021000014504A patent/IT202100014504A1/en unknown
-
2022
- 2022-06-14 WO PCT/IB2022/055491 patent/WO2022254414A2/en active Application Filing
- 2022-06-14 ES ES202390217A patent/ES2963727R1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019239372A1 (en) * | 2018-06-13 | 2019-12-19 | Pharmanutra S.P.A. | Composition comprising sucrosomial minerals containing mineral salts for use in conditions of deficiency of such minerals |
WO2021099976A1 (en) * | 2019-11-19 | 2021-05-27 | Neilos S.r.l. | A nutraceutical or pharmaceutical composition comprising iron pyrophosphate for use in the treatment and/or prevention of conditions or diseases characterized by iron deficiency |
Non-Patent Citations (3)
Title |
---|
"Ultramag Magnesium" hoja de información del producto. Pureencapsulation.com, 01/03/2018, [en línea][recuperado el 13/03/2024]. Recuperado de Internet (URL:https://www.pureencapsulationspro.com/ultramag-magnesium.html), Documento completo. * |
BRILLI, E. ET AL. Magnesium bioavailability after administration of sucrosomial®magnesium:results of an ex-vivo study and comparative, doublé-blinded, cross-over study in healthy subjects. European Review for Medical and Pharmacological Sciences, 01/03/2018, Páginas 1843-1851 [en línea][recuperado el 13/03/2024]. Recuperado de Internet (URL:https://www.europeanreview.org/wp/wp-content/uploads/1843-1851-1.pdf), Documento completo. * |
GÓMEZ-RAMÍREZ, S. ET AL. Sucrosomial®Iron: A New Generation Iron for Improving Oral Supplementation". PHARMACEUTICALS, 04/12/2018, Vol. 11, Páginas 97 [en línea][recuperado el 13/03/2024]. Documento complet. * |
Also Published As
Publication number | Publication date |
---|---|
WO2022254414A3 (en) | 2023-11-23 |
WO2022254414A2 (en) | 2022-12-08 |
IT202100014504A1 (en) | 2022-12-04 |
ES2963727A2 (en) | 2024-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012003026A1 (en) | Pharmaceutical composition comprising pioglitazone and linagliptin; preparation procedure; Use in the treatment of type 2 diabetes or obesity. | |
PL3577135T3 (en) | A pharmaceutical composition for use in the treatment or prevention of c5-related diseases | |
ES2525801T8 (en) | Compositions and methods for the prevention and treatment of autoimmune diseases | |
AR110777A1 (en) | INDANILAMINOPIRAZINILCICLOPROPANCARBOXÍLICOS ACIDS PHARMACEUTICAL COMPOSITIONS AND ITS USES IN THE TREATMENT OF DISEASES MEDIATED BY GPR40 | |
BR112018005905A2 (en) | ? compound, pharmaceutical composition, methods to prevent or treat a disease or condition, organ damage, hepatotoxicity and fatty liver, and, use of a compound? | |
BRPI0819105A2 (en) | composition for the treatment and prevention of eyelid edema | |
CL2007001945A1 (en) | COMPOUNDS DERIVED FROM ALQUILPIRIDAZINA, INHIBITORS OF 11 BETA-HSD1; PROCESS FOR OBTAINING COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT UNDERSTAND THEM; AND USES IN THE TREATMENT OF DIABETES, OBESITY, FOOD INGESTION DISORDER, DISLIPIDE | |
RS65630B1 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease | |
EP4146633A4 (en) | Composition for use in the treatment of apol1-associated disease | |
CL2008003799A1 (en) | Pharmaceutical composition comprising raloxifene in immediate release tablet form; Useful for the treatment and / or prevention of osteoporosis. | |
BRPI0818267A2 (en) | New 1,3-dihydro-5-isobenzofuranocarbonitrile derivatives and their pharmaceutical composition for the treatment of premature ejaculation | |
BR112013014189A2 (en) | pharmaceutical composition comprising transcinamaldehyde and its use in the treatment of infections | |
BRPI0912890A2 (en) | pharmaceutical composition for the treatment of premature ejaculation | |
ES2980790T3 (en) | Structurally improved sulfur-containing fatty acids for use in the treatment of non-alcoholic steatohepatitis | |
CL2012003006A1 (en) | Compounds derived from unsaturated steroid lactones in position 7 (8) and their pharmaceutically acceptable salts and stereoisomers; pharmaceutical composition that includes them; and its use for the treatment of cancer. | |
CL2015000333A1 (en) | Bir2 and / or bir3 inhibitor azaheterocycles; pharmaceutical composition; and use in the treatment of cancer. | |
CL2011001777A1 (en) | Pharmaceutical composition containing aleglitazar; process to prepare said pharmaceutical composition; and its use for the treatment or prophylaxis of type II diabetes or cardiovascular diseases. | |
CL2017000884A1 (en) | Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patients who have undergone gastric bypass surgery | |
IT201900021564A1 (en) | Nutraceutical or pharmaceutical composition including iron pyrophosphate for use in the treatment and / or prevention of conditions or diseases characterized by iron deficiency | |
CL2013000542A1 (en) | Compounds derived from substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides, modulators kcnq2 / 3; pharmaceutical composition; and its use for the treatment or prophylaxis of pain, preferably acute pain, chronic pain, neuropathic pain, visceral pain. epilepsy, migraine, among others. | |
ES2981079T3 (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
ES2963727R1 (en) | Nutraceutical or pharmaceutical composition for use in the treatment and/or prevention of conditions or pathologies characterized by magnesium deficiency | |
CO2019007671A2 (en) | A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of Alzheimer's disease | |
ES2660372T8 (en) | Substances and procedures for use in the prevention and / or treatment of Huntington's disease | |
CO2019002853A2 (en) | Tesofensine compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BA2A | Patent application published |
Ref document number: 2963727 Country of ref document: ES Kind code of ref document: A2 Effective date: 20240401 |
|
EC2A | Search report published |
Ref document number: 2963727 Country of ref document: ES Kind code of ref document: R1 Effective date: 20240426 |